Suppr超能文献

健康与疾病中铁的不稳定状态:一篇综述

The Labile Side of Iron in Health and Disease: A Narrative Review.

作者信息

Cabantchik Ioav Z, Karmi Ola, Nechushtai Rachel

机构信息

The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.

出版信息

Adv Exp Med Biol. 2025;1480:47-60. doi: 10.1007/978-3-031-92033-2_4.

Abstract

Labile iron is an exchangeable and redox-active form of Fe/Fe that is identified in cells under normal or pathological conditions, particularly with the aid of an increasing number of metal-sensitive probes, especially those carrying fluorescent-based sensors, some targetable to specific cell organelles, some useful for real-time measurements. Cell labile iron pools (LIPs) are associated with multiple ligands, predominantly as Fe-GSH adducts, whose chemical identity remains to be firmly identified. Estimated cellular LIP levels are in the lower μMolar range, rising substantially in systemic iron overload, thus serving as targets for screening of drugs for chelation efficacy and protection from oxidative damage, including ferroptosis. Pathological LIP elevation in specific organs and/or cells results from mutations that affect some FeS-cluster (ISC) protein biogenesis, as in Wolfram syndrome-2 (WS2) patients, who lack NAF-1 (a member of the CISD-coded NEET protein family that carries labile ISCs). In cells from WS2 patients or shRNA NAF-1-repressed, there are elevated mitochondrial LIP and ROS together with reduced GSH levels that are accompanied by morphological and functional damage, most significantly correctable by applying anti-ferroptotic measures, including a conservative form of chelation in conjunction with an antioxidant, offering novel opportunities to treat the otherwise incurable WS2.

摘要

不稳定铁是Fe²⁺/Fe³⁺的一种可交换且具有氧化还原活性的形式,在正常或病理条件下的细胞中均可被识别,特别是借助越来越多的金属敏感探针,尤其是那些带有荧光传感器的探针,其中一些可靶向特定细胞器,一些可用于实时测量。细胞不稳定铁池(LIPs)与多种配体相关,主要以Fe-GSH加合物的形式存在,其化学特性仍有待明确鉴定。估计细胞内LIP水平处于较低的微摩尔范围内,在全身性铁过载时会大幅升高,因此可作为筛选具有螯合功效以及预防氧化损伤(包括铁死亡)药物的靶点。特定器官和/或细胞中的病理性LIP升高是由影响某些铁硫簇(ISC)蛋白生物合成的突变引起的,如在沃夫勒姆综合征2型(WS2)患者中,他们缺乏NAF-1(CISD编码的NEET蛋白家族成员,携带不稳定的ISC)。在来自WS2患者或经shRNA抑制NAF-1的细胞中,线粒体LIP和ROS升高,同时GSH水平降低,并伴有形态和功能损伤,通过采取抗铁死亡措施(包括保守形式的螯合与抗氧化剂联合使用)可显著纠正这些损伤,这为治疗原本无法治愈的WS2提供了新的机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验